Toca 511 is a modified retroviral replicating vector based on Moloney γ-retrovirus with an amphotropic envelope. As an investigational cancer treatment, Toca 511 preferentially infects cancer cells without direct cell lysis and encodes an enhanced yeast cytosine deaminase that converts the antifungal drug 5-fluorocytosine to the anticancer drug, 5-fluorouracil. A panel of established human cancer cell lines, derived from glioblastoma, colon, and breast cancer tissue, was used to evaluate parameters critical for effective anticancer activity. Gene transfer, cytosine deaminase production, conversion of 5-fluorocytosine to 5-fluorouracil, and subsequent cell killing occurred in all lines tested. We observed >50% infection within 25 days in all lines and 5-fluorocytosine LD50 values between 0.02 and 6 μg/ml. Although we did not identify a small number of key criteria, these studies do provide a straightforward approach to rapidly gauge the probability of a Toca 511 and 5-fluorocytosine treatment effect in various cancer indications: a single MTS assay of maximally infected cancer cell lines to determine 5-fluorocytosine LD50. The data suggest that, although there can be variation in susceptibility to Toca 511 and 5-fluorocytosine because of multiple mechanistic factors, this therapy may be applicable to a broad range of cancer types and individuals.
Get full access to this article
View all access options for this article.
References
1.
DockG. The influence of complicating diseases upon leukaemia. Am J Med Sci, 1904; 127:561–592.
2.
LoggCR, TaiCK, LoggA, et al.A uniquely stable replication-competent retrovirus vector achieves efficient gene delivery in vitro and in solid tumors. Hum Gene Ther, 2001; 12:921–932.
3.
OstertagD, AmundsonKK, Lopez EspinozaF, et al.Brain tumor eradication and prolonged survival from intratumoral conversion of 5-fluorocytosine to 5-fluorouracil using a nonlytic retroviral replicating vector. Neuro-oncology, 2012; 14:145–159.
4.
HuangTT, HlavatyJ, OstertagD, et al.Toca 511 gene transfer and 5-fluorocytosine in combination with temozolomide demonstrates synergistic therapeutic efficacy in a temozolomide-sensitive glioblastoma model. Cancer Gene Ther, 2013; 20:544–551.
5.
WangWJ, TaiCK, KasaharaN. Highly efficient and tumor-restricted gene transfer to malignant gliomas by replication-competent retroviral vectors. Hum Gene Ther, 2003; 14:117–127.
6.
Rodriguez-AguirreME, EspinozaFL, MartinB, et al.Abstract 708: Toca 511 gene therapy in combination with 5-fluorocytosine for intratumoral production of 5-fluorouracil in a colon cancer metastasis model. Cancer Res, 2014; 74:Abstract 708.
7.
PerezOD, LoggCR, HiraokaK, et al.Design and selection of Toca 511 for clinical use: Modified retroviral replicating vector with improved stability and gene expression. Mol Ther, 2012; 20:1689–1698.
8.
CloughesyTF, KesariS, KalkanisS, et al.IT-05 administration of Toca 511 to subjects with recurrent HGG undergoing repeat resection. 2014. In press.
9.
VermesA, GuchelaarHJ, DankertJ. Flucytosine: A review of its pharmacology, clinical indications, pharmacokinetics, toxicity and drug interactions. J Antimicrob Chemother, 2000; 46:171–179.
10.
LuM, FreytagSO, StrickerH, et al.Adaptive seamless design for an efficacy trial of replication-competent adenovirus-mediated suicide gene therapy and radiation in newly-diagnosed prostate cancer (ReCAP Trial). Contemp Clin Trials, 2011; 32:453–460.
11.
LongleyDB, HarkinDP, JohnstonPG. 5-Fluorouracil: Mechanisms of action and clinical strategies. Nat Rev Cancer, 2003; 3:330–338.
12.
ZhangM, LiS, NyatiMK, et al.Regional delivery and selective expression of a high-activity yeast cytosine deaminase in an intrahepatic colon cancer model. Cancer Res, 2003; 63:658–663.
13.
GmeinerWH. Novel chemical strategies for thymidylate synthase inhibition. Curr Med Chem, 2005; 12:191–202.
14.
SiaKC, HuynhH, ChinnasamyN, et al.Suicidal gene therapy in the effective control of primary human hepatocellular carcinoma as monitored by noninvasive bioimaging. Gene Ther, 2012; 19:532–542.
15.
QiuY, PengG-L, LiuQ-C, et al.Selective killing of lung cancer cells using carcinoembryonic antigen promoter and double suicide genes, thymidine kinase and cytosine deaminase (pCEA-TK/CD). Cancer Lett, 2012; 316:31–38.
16.
WaldorfAR, PolakA. Mechanisms of action of 5-fluorocytosine. Antimicrob Agents Chemother, 1983; 23:79–85.
17.
GutovaM, ShacklefordGM, KhankaldyyanV, et al.Neural stem cell-mediated CE/CPT-11 enzyme/prodrug therapy in transgenic mouse model of intracerebellar medulloblastoma. Gene Ther, 2013; 20:143–150.
18.
KunzC, FockeF, SaitoY, et al.Base excision by thymine DNA glycosylase mediates DNA-directed cytotoxicity of 5-fluorouracil. PLoS Biol, 2009; 7:e91.
19.
MooltenFL. Tumor chemosensitivity conferred by inserted herpes thymidine kinase genes: Paradigm for a prospective cancer control strategy. Cancer Res, 1986; 46:5276–5281.
20.
YiB-R, ChoiKJ, KimSU, et al.Therapeutic potential of stem cells expressing suicide genes that selectively target human breast cancer cells: Evidence that they exert tumoricidal effects via tumor tropism (review). Int J Oncol, 2012; 41:798–804.
21.
WohlhueterRM, McIvorRS, PlagemannPG. Facilitated transport of uracil and 5-fluorouracil, and permeation of orotic acid into cultured mammalian cells. J Cell Physiol, 1980; 104:309–319.
22.
KikuchiE, MenendezS, OzuC, et al.Highly efficient gene delivery for bladder cancers by intravesically administered replication-competent retroviral vectors. Clin Cancer Res, 2007; 13:4511–4518.
23.
KuriyamaS, MasuiK, SakamotoT, et al.Bystander effect caused by cytosine deaminase gene and 5-fluorocytosine in vitro is substantially mediated by generated 5-fluorouracil. Anticancer Res, 1998; 18:3399–3406.
24.
HuberBE, AustinEA, RichardsCA, et al.Metabolism of 5-fluorocytosine to 5-fluorouracil in human colorectal tumor cells transduced with the cytosine deaminase gene: Significant antitumor effects when only a small percentage of tumor cells express cytosine deaminase. Proc Natl Acad Sci USA, 1994; 91:8302–8306.
25.
TsujieM, NakamoriS, NakahiraS, et al.Human equilibrative nucleoside transporter 1, as a predictor of 5-fluorouracil resistance in human pancreatic cancer. Anticancer Res, 2007; 27:2241–2249.
26.
HamstraDA, RiceDJ, FahmyS, et al.Enzyme/prodrug therapy for head and neck cancer using a catalytically superior cytosine deaminase. Hum Gene Ther, 1999; 10:1993–2003.
27.
LawrenceTS, RehemtullaA, NgEY, et al.Preferential cytotoxicity of cells transduced with cytosine deaminase compared to bystander cells after treatment with 5-flucytosine. Cancer Res, 1998; 58:2588–2593.
28.
RamnaraineM, PanW, GoblirschM, et al.Direct and bystander killing of sarcomas by novel cytosine deaminase fusion gene. Cancer Res, 2003; 63:6847–6854.
29.
KucerovaL, MatuskovaM, PastorakovaA, et al.Cytosine deaminase expressing human mesenchymal stem cells mediated tumour regression in melanoma bearing mice. J Gene Med, 2008; 10:1071–1082.
30.
ChalikondaS, KivlenMH, O'MalleyME, et al.Oncolytic virotherapy for ovarian carcinomatosis using a replication-selective vaccinia virus armed with a yeast cytosine deaminase gene. Cancer Gene Ther, 2008; 15:115–125.
31.
GoodmanLS. Goodman and Gilman's the Pharmacological Basis of Therapeutics. (McGraw-Hill, New York, NY). 1996.
32.
MichaelsenSR, ChristensenCL, SehestedM, et al.Single agent- and combination treatment with two targeted suicide gene therapy systems is effective in chemoresistant small cell lung cancer cells. J Gene Med, 2012; 14:445–458.
33.
TakahashiM, ValdesG, HiraokaK, et al.Radiosensitization of gliomas by intracellular generation of 5-fluorouracil potentiates prodrug activator gene therapy with a retroviral replicating vector. Cancer Gene Ther, 2014; 21:405–410.
34.
StolworthyTS, KorkegianAM, WillmonCL, et al.Yeast cytosine deaminase mutants with increased thermostability impart sensitivity to 5-fluorocytosine. J Mol Biol, 2008; 377:854–869.
35.
SeitherRL, TrentDF, MikuleckyDC, et al.Effect of direct suppression of thymidylate synthase at the 5,10-methylenetetrahydrofolate binding site on the interconversion of tetrahydrofolate cofactors to dihydrofolate by antifolates. Influence of degree of dihydrofolate reductase inhibition. J Biol Chem, 1991; 266:4112–4118.
RobbinsJM, JollyDJ, OstertagDG, et al.Cancer combination therapy and recombinant vectors. US 20140178340 A1.
38.
ChenJK, HuLJ, WangD, et al.Cytosine deaminase/5-fluorocytosine exposure induces bystander and radiosensitization effects in hypoxic glioblastoma cells in vitro. Int J Radiat Oncol Biol Phys, 2007; 67:1538–1547.
39.
MillerCR, WilliamsCR, BuchsbaumDJ, et al.Intratumoral 5-fluorouracil produced by cytosine deaminase/5-fluorocytosine gene therapy is effective for experimental human glioblastomas. Cancer Res, 2002; 62:773–780.
40.
HlavatyJ, JandlG, LisztM, et al.Comparative evaluation of preclinical in vivo models for the assessment of replicating retroviral vectors for the treatment of glioblastoma. J Neurooncol, 2010; 102:59–69.
41.
NealJW, GainorJF, ShawAT. Developing biomarker-specific end points in lung cancer clinical trials. Nat Pub Group, 2014; 12:135–146.
42.
DietelM, JöhrensK, LaffertM, et al.Predictive molecular pathology and its role in targeted cancer therapy: A review focussing on clinical relevance. Cancer Gene Ther, 2013; 20:211–221.
43.
KimD, PerteaG, TrapnellC, et al.TopHat2: Accurate alignment of transcriptomes in the presence of insertions, deletions and gene fusions. Genome Biol, 2013; 14:R36.
44.
TrapnellC, HendricksonDG, SauvageauM, et al.Differential analysis of gene regulation at transcript resolution with RNA-seq. Nat Biotechnol, 2013; 31:46–53.
45.
AndersS, PylPT, HuberW. HTSeq-a Python framework to work with high-throughput sequencing data. Bioinformatics, 2015; 31:166–169.
46.
LiJ, TibshiraniR. Finding consistent patterns: A nonparametric approach for identifying differential expression in RNA-Seq data. Stat Methods Med Res, 2013; 22:519–536.
47.
RoeT, ReynoldsTC, YuG, et al.Integration of murine leukemia virus DNA depends on mitosis. EMBO J, 1993; 12:2099–2108.
48.
NishiyamaT, KawamuraY, KawamotoK, et al.Antineoplastic effects in rats of 5-fluorocytosine in combination with cytosine deaminase capsules. Cancer Res, 1985; 45:1753–1761.
49.
DamarajuVL, DamarajuS, YoungJD, et al.Nucleoside anticancer drugs: The role of nucleoside transporters in resistance to cancer chemotherapy. Oncogene, 2003; 22:7524–7536.
50.
SunX, XingL, DengX, et al.Hypoxia targeted bifunctional suicide gene expression enhances radiotherapy in vitro and in vivo. Radiother Oncol, 2012; 105:57–63.
51.
van KuilenburgABP, MeinsmaR, ZonnenbergBA, et al.Dihydropyrimidinase deficiency and severe 5-fluorouracil toxicity. Clin Cancer Res, 2003; 9:4363–4367.
52.
LecomteT. Thymidylate synthase gene polymorphism predicts toxicity in colorectal cancer patients receiving 5-fluorouracil-based chemotherapy. Clin Cancer Res, 2004; 10:5880–5888.
53.
TrinhQT, AustinEA, MurrayDM, et al.Enzyme/prodrug gene therapy: Comparison of cytosine deaminase/5-fluorocytosine versus thymidine kinase/ganciclovir enzyme/prodrug systems in a human colorectal carcinoma cell line. Cancer Res, 1995; 55:4808–4812.
54.
GuoX, GoesslE, JinG, et al.Cell cycle perturbation and acquired 5-fluorouracil chemoresistance. Anticancer Res, 2008; 28:9–14.
55.
LewisPF, EmermanM. Passage through mitosis is required for oncoretroviruses but not for the human immunodeficiency virus. J Virol, 1994; 68:510–516.
56.
LoweDB, BoseA, TaylorJL, et al.Dasatinib promotes the expansion of a therapeutically superior T-cell repertoire in response to dendritic cell vaccination against melanoma. OncoImmunology, 2014; 3:e27589.
57.
BeckerJC, AndersenMH, SchramaD, et al.Immune-suppressive properties of the tumor microenvironment. Cancer Immunol Immunother, 2013; 62:1137–1148.
58.
LouisDN. Molecular pathology of malignant gliomas. Annu Rev Pathol Mech Dis, 2006; 1:97–117.
59.
MullenCA, CoaleMM, LoweR, et al.Tumors expressing the cytosine deaminase suicide gene can be eliminated in vivo with 5-fluorocytosine and induce protective immunity to wild type tumor. Cancer Res, 1994; 54:1503–1506.
BennettJE, DismukesWE, DumaRJ, et al.A comparison of amphotericin B alone and combined with flucytosine in the treatment of cryptoccal meningitis. N Engl J Med, 1979; 301:126–131.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
